Thu, Dec 18, 2014, 3:40 PM EST - U.S. Markets close in 20 mins.

Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • kolemup kolemup Feb 13, 2013 5:43 PM Flag

    Almost 13 Thousand in study....Fish oil is same as Placebo!!!

    It's little wonder AMRN failed to find a partner and raised money instead at high interest rates to "go at it alone." They need to hire a huge sales force it seems to push their fish oil. Other studies have shown similar negative conclusions regarding fish oil's benefits. For example, researchers at McMaster University conducted a study with 12,536 patients concluded fish oil was no better than placebo. A number of other recent studies have been coming to the same or similar conclusions.

    The only other FDA approved prescription fish oil pill is GlaxoSmithKline' (GSK) called Lovaza. Lovaza has been seeing a decline in prescriptions in recent months. It seems that doctors are wising up. With healthcare costs already out of control, do patients really need an expensive prescription for another fish oil pill with the exact same active ingredients as the cheaper OTC versions? Here's an example of one doctor swearing he'll never write another prescription for Lovaza again due to the unethical costs to...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It was Epadel (Japanese name for Vascepa) that "ruined" that JAMA meta study..

      ""The Japanese, open-label, high-baseline-intake, mainly primary prevention JELIS trial, predominantly in women, failed to replicate the GISSI trial for the outcomes assessed (sudden and cardiac death) even in the secondary prevention subgroup analysis."

      From "Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events A Systematic Review and Meta-analysis."

      JAMA September 12, 2012, Vol 308, No. 10

      Sentiment: Strong Sell

 
AMRN
1.030.00(0.00%)3:39 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.